Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. 더 보기
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – –...
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.25203252033 | 1.23 | 1.39 | 1.11 | 2130851 | 1.21309592 | CS |
4 | -0.31 | -20.6666666667 | 1.5 | 1.6 | 1.03 | 2318454 | 1.26076488 | CS |
12 | 0.39 | 48.75 | 0.8 | 2.43 | 0.7 | 5252530 | 1.50692958 | CS |
26 | -0.13 | -9.84848484848 | 1.32 | 2.43 | 0.6603 | 3691996 | 1.32796609 | CS |
52 | -0.82 | -40.7960199005 | 2.01 | 2.87 | 0.6603 | 2861250 | 1.60148356 | CS |
156 | -11.01 | -90.2459016393 | 12.2 | 14.11 | 0.6603 | 2556138 | 3.67857878 | CS |
260 | -18.11 | -93.8341968912 | 19.3 | 23.03 | 0.6603 | 1934885 | 6.47053477 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관